Methods. MDA and 4-hydroxynonenal (HNE) were. There is increasing evidence that oxygen radicals are measured in three groups of patients undergoing HD:.
Nephrol Dial Transplant (1998) 13: 2583–2587
Nephrology Dialysis Transplantation
Brief Report
Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Olaf Sommerburg1, Tilman Grune2, Hannelore Hampl3, Eberhard Riedel4, Frederik J. M. G. van Kuijk5, Jochen H. H. Ehrich1 and Werner G. Siems6 1Paediatric Nephrology and 2Department of Physical Therapy and Rehabilitation, Charite´ Hospital, Schumannstrasse 20/21, 10098 Berlin, 3Department of Nephrology and 4Department of Chemistry, Free University of Berlin, Limonenstrasse 7, 10456 Berlin, 6Herzog Julius Hospital, Kurhausstrasse 13–17, 38655 Bad Harzburg, Germany and 5University of Texas Medical Branch, Medical Research Building 7–150, Galveston, TX 77555–1067, USA
Abstract Background. Patients with end-stage renal failure undergoing haemodialysis (HD) are exposed to oxidative stress. Increased levels of malondialdehyde (MDA) were demonstrated in plasma of uraemic patients, indicating accelerated lipid peroxidation (LPO) as a consequence of multiple pathogenetic factors. The aim of our investigation was to examine the role of renal anaemia in oxidative stress in HD patients. Methods. MDA and 4-hydroxynonenal (HNE) were measured in three groups of patients undergoing HD: group I comprised eight patients with a blood haemoglobin (Hb) 10 g/dl (mean Hb=12.4±1.9 g/dl ); none of these 16 patients had been treated with human recombinant erythropoietin (rHuEpo). Group III comprised 27 patients with a mean Hb of 10.5±1.6 g/dl after long-term rHuEpo treatment. Results. Mean plasma concentrations of both MDA and HNE were significantly higher (P6 months (total dosage 7000–12 000 IE/week). None of the patients of group I and II had been treated with rHuEpo; they received transfusions, vitamin B and folate supplementation, if 12 necessary. All patients underwent bicarbonate dialysis, and were dialysed for 4–5 h three times weekly. In each group, half the patients were dialysed with cuprophane membranes, while the others were dialysed with biocompatible membranes. The same type of membrane was used for each patient 4 months before and during the study. Whatever the type of membrane used, we observed no difference in the result of the present study. Age, gender, characteristics of dialysis and underlying renal disorders of the patients of the studied groups are listed in Table 1. Twenty healthy subjects (10 male, 10 female), mean age=59 years (range 47–79), were chosen as controls. HNE and MDA concentrations were determined in blood plasma. Blood was taken from patients in K-EDTA monovettes prepared with butylated hydroxytoluene (BHT, final concentration 10 mg/ml ) just before the start of HD treatment during regular out-patients visits. After separation from erythrocytes, plasma was stored immediately in liquid nitrogen.
Statistics The statistical significance of the data was determined by the Mann–Whitney rank sum test and polynomial regression analysis. Differences were considered to be statistically significant if P
